Free Trial
NASDAQ:DYAI

Dyadic International Q2 2025 Earnings Report

Dyadic International logo
$1.01 +0.01 (+0.50%)
Closing price 08/4/2025 04:00 PM Eastern
Extended Trading
$1.01 +0.00 (+0.10%)
As of 08/4/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyadic International EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Dyadic International Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dyadic International Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Dyadic International Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Dyadic International, Inc. (DYAI) - Yahoo Finance
See More Dyadic International Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dyadic International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyadic International and other key companies, straight to your email.

About Dyadic International

Dyadic International (NASDAQ:DYAI), Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

View Dyadic International Profile

More Earnings Resources from MarketBeat